With the development of techniques for the qualitative and quantitative assessment of receptor function and knowledge of the biological responsiveness of neurotransmitter-mediated pathways, it is now quite clear that the response of a patient to a drug does not only involve the concentration of the drug in blood and tissue. Number and function of receptors are also important factors. A perturbation in which the receptor number is elevated is called "up-regulation", whereas "down-regulation" refers to the uncoupling between receptor and effector and the consecutive decrement in the receptor concentration. In general, there is an inverse relationship between the ambient concentration of the agonist and the number of its receptors and, therefore, the sensitivity of the target organ. The demarcation between alpha- and beta-adrenergic receptors has long been appreciated. Recent advances in the understanding of adrenergic receptors have led to the subdivision of beta-receptors; beta 1-adrenoceptors mediate the stimulation of rate and force of cardiac contraction and stimulate lipolysis. beta 2-adrenoceptors mediate smooth muscle relaxation and facilitate glycogenolysis and the release of insulin, glucagon and renin. The alpha-adrenergic receptors may also be divided into two subgroups. The alpha 1-adrenoceptors are postsynaptic located and facilitate smooth muscle constriction. Presynaptic located alpha 2-adrenoceptors mediate feedback inhibition of norepinephrine-release, while postsynaptic alpha 2-adrenoceptors facilitate smooth muscle contraction in selected vascular beds and stimulate the inhibition of various metabolic processes (insulin and renin secretion, lipolysis). The stage is now set for the application of the new knowledge of receptor function and regulation to the advancement of the practice of anaesthesia and intensive care.
随着受体功能定性和定量评估技术的发展以及对神经递质介导途径生物反应性的认识,现在很清楚,患者对药物的反应不仅涉及药物在血液和组织中的浓度。受体的数量和功能也是重要因素。受体数量增加的扰动称为“上调”,而“下调”是指受体与效应器之间的解偶联以及随后受体浓度的降低。一般来说,激动剂的周围浓度与其受体数量以及靶器官的敏感性之间存在反比关系。α-和β-肾上腺素能受体之间的区分早已为人所知。对肾上腺素能受体理解的最新进展导致了β-受体的细分;β1-肾上腺素能受体介导心脏收缩速率和力量的刺激并刺激脂肪分解。β2-肾上腺素能受体介导平滑肌松弛并促进糖原分解以及胰岛素、胰高血糖素和肾素的释放。α-肾上腺素能受体也可分为两个亚组。α1-肾上腺素能受体位于突触后,促进平滑肌收缩。位于突触前的α2-肾上腺素能受体介导去甲肾上腺素释放的反馈抑制,而位于突触后的α2-肾上腺素能受体促进选定血管床中的平滑肌收缩并刺激各种代谢过程(胰岛素和肾素分泌、脂肪分解)的抑制。现在是将受体功能和调节的新知识应用于麻醉和重症监护实践进步的时候了。